The haematological system and skin - Coagulation and the bone marrow in health and disease Flashcards
Thrombophilias - who should be screened
Patients with thrombosis who are young
Positive family history
Thrombosis in an unusual site
Recurrence
Females with recurrent foetal loss
Inherited thrombophilias
Factor V Leiden
Protein C deficiency
Protein S deficiency
Antithrombin III deficiency
Prothrombin mutation
Acquired thrombophilia
Oestrogen therapy, contraceptive pill
Malignancy
Pregnancy and puerperium
Lupus anticoagulant (antiphospholipid) syndrome
Raised plasma homocysteine (may also be inherited)
Lupus anticoagulant (antiphospholipid) syndrome - clinical features
CLOT
Clots: arterial/venous thrombosis
Lived reticularis
Obstretic loss: recurrent miscarriages
Thrombocytopenia
Lupus anticoagulant (antiphospholipid) syndrome - laboratory features
Prolonged APTT
Lupus anticoagulant (antiphospholipid) syndrome - Management
Lifelong anticoagulation
Management of warfarin - major bleeding
Stop warfarin
Administer IV vitamin K
Administer prothrombin complex ( or fresh frozen plasma if prothrombin complex unavailable)
Management of warfarin - minor bleeding
Stop anticoagulants
Administer IV vitamin K
Repeat INR after 24 hours, may need further vitamin K
Management of warfarin - no bleeding with INR > 8
Stop anticoagulants
Administer IV or oral vitamin K
Repeat INR after 24 hours
Management of warfarin - no bleeding with INR between 5-8
Withhold 1-2 doses of warfarin and restart at reduced dose
Review maintenance dose of warfarin
Heparin - management of over anticoagulation/bleeding
Stop heparin – short half-life, may be sufficient
Local measures e.g., apply pressure
Consider tranexamic acid
If bleeding, consider protamine sulphate
Look for cause e.g., incorrect dose, new renal failure
Before restarting check risk: benefit ratio
DOAC - management of anticoagulation/bleeding
- Stop DOAC
- Local measures e.g., apply pressure
- Consider tranexamic acid
Idracruzimab reveral agent for dabigatran
- Antidote to Xa inhibitors not yet available. In the meantime, in life threatening bleeding consider prothrombin complex concentrate
- Look for cause
- Before restarting check risk:benefit ration
Warfarin: risk factors for bleeding
- Elderly
- Renal failure
- Liver failure
- Recurrent falls
- Platelet of NSAIDs use
- Alcoholism
- Cancer
Leucocytosis - causes
Primary
- Leukaemia/ lymphoma/ myeloproliferative disorders
Secondary
- infection
- Inflammation
- Infarction
- Tumour
Thrombocytosis - causes
Primary - essential thrombocythemia
Secondary
- Infection
- Inflammation
- Infarction
- Tumour
Essential thrombocythemia - aetiology and pathophysiology
JAK2 mutation in 50% cases
Essential thrombocythemia - clinical features
Asymptomatic - at least 30%
Thrombosis (arterial/venous)
Headaches, visual disturbances
Excessive haemorrhage may occur spontaneously or after trauma or surgery
Pruritis and sweating are uncommon
Gout (raises uric acid)
Essential thrombocythemia - laboratory features
Raised platelet count
Raised red cell and/or white cell in 30%
Blood film - platelet anisocytosis with circulating megakarocyte fragments. Auto infraction of the spleen may case target cells, Howell-Jolly bodies
JAK2 mutation
Raised serum uric acid
Serum LDH normal
Bone marrow - hyper cellular + increased megakarocytes
Essential thrombocythemia - management
Aspirin only in younger patients < 40 years
Chemotherapy with hydroxycarbamide + aspirin in > 40 years
Alpha interferon (may be used in younger patients but needs injections and has side- effects - flu like symptoms)
Allopurinol for gout
True erythrocytosis “polycythaemia” - definition and causes
Definition
- Increased number of red cells
Causes
- Primary: Polycythaemia rubra vera
- Secondary: low oxygen e.g., cold, tumours, doping, high affinity haemoglobin
Apparent erythrocytosis - defenition and causes
Definition
- Reduced plasma volume
Causes
- Smoking
- Overweight
- Alcohol excess
- Medications e.g., diuretics
Polycythaemia rubra vera - aetiology and pathophysiology
Mutations of JAK2 in > 995% cases
Polycythaemia rubra vera - clinical features
- Aquagenic pruritus (itchiness after hot bath especially)
- ‘Ruddy complexion’/plethora/redness
- Teaches and visual disturbances
- Thrombosis (arterial/venous)
- Haemorrhage especially GI
- Splenomegaly
- Hyperviscosity symptoms: chest pain, myalgia, weakness, headache, blurred vision, loss of concentration
Polycythaemia rubra vera - Laboratory features
- Raised hb, haemoatocrit and red cell count
- Raised white cells and/or platelets (in 75% people)
- JAK2 mutation
- Raised serum uric acid
- Serum LDH normal or slightly raised
- Low serum EPO (to prevent further erythrocytosis)
- Hypercellular bone marrow with deplete iron stores
Polycythaemia rubra vera - management
Venesection +/- chemotherapy with oral hydroxycarbamide + aspirin
Plasmapheresis for hyperviscosity syndrome
PPI for patients with indigestion or history of GI bleeding
Allopurinol to prevent hyperuricemia
Polycythaemia rubra vera - prognosis
Development of myelofibrosis (in up to 30%
AML (in ups o 5%, not increased by hyrdoxycarbamide)
Thrombocytopenia - causes
Underproduction
- Drugs affect stem cell
- Liver failure
- Part of pancytopenia due to marrow failure
Peripheral destruction
- Autoimmune (ITP)
- Hypersplenism
- Drugs
- Infection/inflammation/ sepsis
Low blood counts caused by reduced production - causes
Myeloma
Myelodysplasia
Metastatic malignancy
Myelofibrosis
Leukaemia
Lymphoma
Aplastic anaemia
Haematinic deficiency
Immune thrombocytopenia purpura (ITP) - definition
Autoimmune disease of Unkown cause where the number of platelets is reduced
Immune thrombocytopenia purpura (ITP) - clinical features
Isolated thrombocytopenia:
- On incidental finding or
- Features of purpura or
- Other minor bleeding